Cover Image
市場調查報告書

濕疹:開發中產品分析

Eczema - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 264103
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
濕疹:開發中產品分析 Eczema - Pipeline Review, H2 2014
出版日期: 2014年09月15日 內容資訊: 英文 45 Pages
簡介

濕疹是皮膚發炎引起的皮膚症狀。常見的症狀有水疱、發癢、發紅、皮膚乾燥等。致病要素有遺傳、環境要素、過敏等。治療方法包含抗組織胺藥物,抗生素,免疫抑制劑等。

本報告提供濕疹的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

濕疹概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Merck & Co., Inc.
  • Celsus Therapeutics Plc
  • China Biologic Products, Inc.
  • GlycaNova Norway AS
  • Immune Response BioPharma, Inc.

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各類型分子

藥物簡介

  • desloratadine
  • MRX-6
  • Varicella Hyperimmune Globulins
  • IR-444
  • MM-1501

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5510IDB

Summary

Global Markets Direct's, 'Eczema - Pipeline Review, H2 2014', provides an overview of the Eczema's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eczema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eczema and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Eczema
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Eczema and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Eczema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Eczema pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Eczema
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Eczema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Eczema Overview
  • Therapeutics Development
    • Pipeline Products for Eczema - Overview
    • Pipeline Products for Eczema - Comparative Analysis
  • Eczema - Therapeutics under Development by Companies
  • Eczema - Therapeutics under Investigation by Universities/Institutes
  • Eczema - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Eczema - Products under Development by Companies
  • Eczema - Products under Investigation by Universities/Institutes
  • Eczema - Companies Involved in Therapeutics Development
    • Merck & Co., Inc.
    • FAES Farma SA
    • China Biologic Products, Inc.
    • GlycaNova Norway AS
    • Immune Response BioPharma, Inc.
  • Eczema - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • bilastine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • desloratadine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Atopic Dermatitis and Eczema - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Varicella Hyperimmune Globulins - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-444 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MM-1501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Eczema - Recent Pipeline Updates
  • Eczema - Dormant Projects
  • Eczema - Discontinued Products
  • Eczema - Product Development Milestones
    • Featured News & Press Releases
      • Oct 21, 2013: Celsus Therapeutics' MRX-6 Selected as One of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence
      • Nov 05, 2012: Creabilis Receives £1.42m Biomedical Catalyst Grant For Development Of CT327
      • Jul 11, 2012: US Government Expands Population Eligible To Receive Bavarian Nordic's Smallpox Vaccine In Emergency
      • Jun 25, 2012: Flower power may be answer to itchy problem
      • May 04, 2012: Anacor To Present Clinical Data On AN2728 At Upcoming Medical Meetings
      • Apr 20, 2012: HanAll BioPharma Initiates Phase II Trial Of Anti-Atopic Dermatitis Gel In US
      • Feb 07, 2012: Anacor Announces Positive Preliminary Results From Two Safety Studies Of AN2728
      • Dec 12, 2011: Anacor Announces Positive Preliminary Results From Phase IIa Trial Of AN2728 In Atopic Dermatitis
      • Dec 12, 2011: Anacor Pharmaceuticals Announces Positive Preliminary Results From Phase IIa Trial Of AN2898 In Atopic Dermatitis
      • May 27, 2011: Creabilis Presents CT327 To 22nd World Congress Of Dermatology In Seoul, Korea
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Eczema, H2 2014
  • Number of Products under Development for Eczema - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Eczema - Pipeline by Merck & Co., Inc., H2 2014
  • Eczema - Pipeline by FAES Farma SA, H2 2014
  • Eczema - Pipeline by China Biologic Products, Inc., H2 2014
  • Eczema - Pipeline by GlycaNova Norway AS, H2 2014
  • Eczema - Pipeline by Immune Response BioPharma, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Eczema Therapeutics - Recent Pipeline Updates, H2 2014
  • Eczema - Dormant Projects, H2 2014
  • Eczema - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Eczema, H2 2014
  • Number of Products under Development for Eczema - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top